Alaunos Therapeutics, Inc. Other Asset Impairment Charges
Alaunos Therapeutics, Inc. (TCRT) reported Other Asset Impairment Charges of $100.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherAssetImpairmentCharges · last filed 2023-03-07
- Alaunos Therapeutics, Inc. other asset impairment charges for fiscal 2021 was $100.00K.
| Period end | Other Asset Impairment Charges 12 month |
|---|---|
| 2021-12-31 | $100.00K 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |